From Bench to Bulk: Overcoming the Scale-Up Barriers of Lipid Nanoparticles (LNPs)
In the modern oncology and rare disease landscape, the most promising therapeutic candidates—such as mRNA, siRNA, and high-potency APIs (HPAPIs)—often suffer from poor aqueous solubility or rapid systemic degradation. Lipid Nanoparticles (LNPs) have emerged as the gold standard for delivering these “hard-to-make” drugs, yet many programs stall during the transition from laboratory bench to clinical production. The […]
Read more
May 15, 2026
